

## Peer Review File

Article Information: <https://dx.doi.org/10.21037/cco-22-104>

### Reviewer A

--In the introduction (lines 18-20), I recommend including the median DOR for BCMA-directed CAR-T agents. CARTITUDE-1 update at ASCO2023 with mDOR 33.9 months; KarMMa3 update published in NEJM 2023 with mDOR of 14.8 months.

--For lines 105-107: I would rephrase this sentence so it is clear that 7.8 months refers to DOR, and not median follow-up (what "it" represents is unclear).

**-Thank you very much for the helpful review. As recommended, the DORs of KarMMa3 and Cartitude-1 are now included in the manuscript and the references are cited.**

**-The text in former lines 105-107 was revised to clarify the DOR is meant.**

### Reviewer B

The editorial is well written. Some mention of recent articles from Baylis et Al regarding mutations in gpre5d and silencing by methylation should be mentioned as future application should consider intact antigen expression before cart application.

**-Thank you, very good point. The work by Nizar Bahlis (Lee H et al. ref #19) is included and the mechanism of antigen escape is now explicitly mentioned in the text.**